An Open-Label, Phase II Trial of Patupilone (EPO906) as Monotherapy to Evaluate Activity of Patupilone in Patients With Advanced Unresectable and/or Metastatic Hepatocellular Carcinoma (HCC).
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2017
At a glance
- Drugs Patupilone (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 05 Apr 2012 Actual patient number changed from 65 to 25 as reported by ClinicalTrials.gov.
- 24 Mar 2011 Actual end date (Oct 2006) added as reported by ClinicalTrials.gov.
- 22 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.